We also undertook several experimental approaches to delineate the interactions between apalutamide therapy, AR and the signal pathways essential for prostate cancer cell survival, and have identified the targets as potential causes for resistance to apalutamide that could be further studied and potentially exploited to counter cancer cell survival. This evidence concerns the gene AR and prostate carcinoma.